Lucía González Cortijo
Lucía González Cortijo
HEAD OF SERVICE
See more specialists on
Madridmadrid
en/medical-staff/oncologist
Key information
- Latest Publication:Clinical characteristics and outcomes among hospitalized adults with severe COVID-19 admitted to a tertiary medical center and receiving antiviral, antimalarials, glucocorticoids, or immunomodulation with tocilizumab or cyclosporine: A retrospective observational study (COQUIMA cohort).
Professional Details
Hospital Universitario Quirónsalud Madrid
HEAD OF SERVICE
February 2009
Olympia Centro Médico Pozuelo
HEAD OF SERVICE
September 2025
Hospital Universitario Quirónsalud Madrid
Specialist doctor
February 2009
MD Anderson International España
Specialist doctor
February 2002
Study
Bachelor of Medicine and Surgery
university, Universidad Autónoma de Madrid
1996
Doctorate
Universidad Autónoma de Madrid
2018
Specialized Healthcare Training
Specialization in Medical Oncology
hospital
Language
Preliminary in English
Language
Certificate of Proficiency in English
Language
Endorsement to Certificate of Proficiency in English: Literature
Language
Endorsement to Certificate of Proficiency in English: Translation from English into Spanish
Language
First Certificate in English
Another qualification
PADIS (Senior Management Program in Healthcare Institutions)
school
Another qualification
Master's Degree in Molecular Oncology
institute
Another qualification
Career Advancement and Leadership for Women in Healthcare
university
Medical Oncology
Universidad Europea de Madrid
Phase II-III studies in breast and gynecological cancer
Run in Pink
2015
La Vida en Rosa Foundation
2017
Translational research line on exercise and breast cancer
Chair of Practice at the Universidad Europea de Madrid
Clinical characteristics and outcomes among hospitalized adults with severe COVID-19 admitted to a tertiary medical center and receiving antiviral, antimalarials, glucocorticoids, or immunomodulation with tocilizumab or cyclosporine: A retrospective observational study (COQUIMA cohort).
Journal Article
Correction: SEOM-GEICAM-SOLTI clinical guidelines for early-stage breast cancer (2022).
Published Erratum
Defining a Standard Set of Patient-Reported Outcomes for Patients With Advanced Ovarian Cancer.
Journal Article
Immuno-priming durvalumab with bevacizumab in HER2-negative advanced breast cancer: a pilot clinical trial.
Journal Article
Mesothelial-to-Mesenchymal Transition and Exosomes in Peritoneal Metastasis of Ovarian Cancer.
Journal Article, Review
MRI guided ROLL/SNOLL in breast cancer patients treated with neoadjuvant chemotherapy.
Journal Article
Palbociclib combined with endocrine therapy in heavily pretreated HR+/HER2- advanced breast cancer patients: Results from the compassionate use program in Spain (PALBOCOMP).
Journal Article
Phosphoproteomic analysis of neoadjuvant breast cancer suggests that increased sensitivity to paclitaxel is driven by CDK4 and filamin A.
Journal Article
Plitidepsin for the management of a cancer patient infected with SARS-CoV-2 while receiving chemotherapy.
Case Reports, Letter
Real world data on the demographic and clinicopathological profile and management of patients with early-stage HER2-positive breast cancer and residual disease treated with adjuvant trastuzumab emtansine (KARMA study).
Journal Article
SEOM-GEICAM-SOLTI clinical guidelines for early-stage breast cancer (2022).
Journal Article
Targeting carcinoma-associated mesothelial cells with antibody-drug conjugates in ovarian carcinomatosis.
Journal Article
Usefulness and real-world outcomes of next generation sequencing testing in patients with cancer: an observational study on the impact of selection based on clinical judgement.
Journal Article
English
Bilingual
Make an appointment with this professional
